Cargando…

MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial

Aim: Between 2012-2015, the PEPaNIC randomized controlled trial, which included 1440 critically ill infants and children, showed that withholding parenteral nutrition during the first week in the pediatric intensive care unit (PICU) (late-PN), as compared with initiating supplemental PN early (early...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, An, Dulfer, Karolijn, Eveleens, Renate, Hordijk, José, Cleemput, Hanna Van, Verlinden, Ines, Wouters, Pieter, Mebis, Liese, Guerra, Gonzalo Garcia, Joosten, Koen, Verbruggen, Sascha, Güiza, Fabian, Vanhorebeek, Ilse, den Berghe, Greet Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209307/
http://dx.doi.org/10.1210/jendso/bvaa046.2116
_version_ 1783531047663697920
author Jacobs, An
Dulfer, Karolijn
Eveleens, Renate
Hordijk, José
Cleemput, Hanna Van
Verlinden, Ines
Wouters, Pieter
Mebis, Liese
Guerra, Gonzalo Garcia
Joosten, Koen
Verbruggen, Sascha
Güiza, Fabian
Vanhorebeek, Ilse
den Berghe, Greet Van
author_facet Jacobs, An
Dulfer, Karolijn
Eveleens, Renate
Hordijk, José
Cleemput, Hanna Van
Verlinden, Ines
Wouters, Pieter
Mebis, Liese
Guerra, Gonzalo Garcia
Joosten, Koen
Verbruggen, Sascha
Güiza, Fabian
Vanhorebeek, Ilse
den Berghe, Greet Van
author_sort Jacobs, An
collection PubMed
description Aim: Between 2012-2015, the PEPaNIC randomized controlled trial, which included 1440 critically ill infants and children, showed that withholding parenteral nutrition during the first week in the pediatric intensive care unit (PICU) (late-PN), as compared with initiating supplemental PN early (early-PN), improved PICU outcomes (1) and improved neurocognitive development assessed 2 years later (2). The latter was explained by avoiding early-PN induced adversely altered DNA-methylation of 37 CpG sites (3). As a large number of patients were younger than 1 year of age at randomization and given that assessment of most neurocognitive domains is only possible from 4 years of age onwards, we performed a 4-year follow-up to determine the impact of late-PN versus early-PN on physical, neurocognitive, and emotional/behavioral development. This pre-planned, 4-year follow-up study of the 1440 PEPaNIC patients and of 369 matched healthy children was blinded for treatment allocation (ClinicalTrials.gov-NCT01536275). Methods: Studied clinical outcomes included anthropometrics, health status, parent/caregiver-reported executive functions, and emotional/behavioral problems, and clinical tests for intelligence, visual-motor integration, alertness, motor coordination and memory. Univariable and multivariable linear and logistic regression analyses adjusted for risk factors assessed the impact of late-PN versus early-PN on the outcomes and investigated a potential mediation role of the adversely altered DNA-methylation of 37 CpG sites previously shown to be evoked by late-PN as compared with early-PN (3). Results: Overall, at 4 years follow-up, patients (356 late-PN patients, 328 early-PN patients) could be tested neurocognitively. They revealed worse anthropometric, health status, neurocognitive and emotional/behavioral developmental outcomes than the healthy control children. Outcomes of late-PN patients were never worse than those of early-PN patients. In contrast, late-PN patients had fewer internalizing (P=0.042) and externalizing problems (P=0.046), and fewer total emotional/behavioral problems (P=0.007) than early-PN patients, which were normalized by late-PN. Avoiding the early-PN induced adversely altered DNA-methylation status of the 37 CpG sites statistically explained its impact on the behavioral outcomes. Conclusion: Four years after randomization to late-PN or early-PN in the PICU, late-PN did not show harm, and was found to protect against emotional/behavioral problems, with altered DNA-methylation as a potential biological mediator hereof. These data further support de-implementation of PN-use early during critical illness in infants and children. (1) Fivez et al. N Eng J Med 2016 (2) Verstraete et al. Lancet Respir Med 2019 (3) Guiza et al. Lancet Respir Med 2020 (in press)
format Online
Article
Text
id pubmed-7209307
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72093072020-05-13 MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial Jacobs, An Dulfer, Karolijn Eveleens, Renate Hordijk, José Cleemput, Hanna Van Verlinden, Ines Wouters, Pieter Mebis, Liese Guerra, Gonzalo Garcia Joosten, Koen Verbruggen, Sascha Güiza, Fabian Vanhorebeek, Ilse den Berghe, Greet Van J Endocr Soc Pediatric Endocrinology Aim: Between 2012-2015, the PEPaNIC randomized controlled trial, which included 1440 critically ill infants and children, showed that withholding parenteral nutrition during the first week in the pediatric intensive care unit (PICU) (late-PN), as compared with initiating supplemental PN early (early-PN), improved PICU outcomes (1) and improved neurocognitive development assessed 2 years later (2). The latter was explained by avoiding early-PN induced adversely altered DNA-methylation of 37 CpG sites (3). As a large number of patients were younger than 1 year of age at randomization and given that assessment of most neurocognitive domains is only possible from 4 years of age onwards, we performed a 4-year follow-up to determine the impact of late-PN versus early-PN on physical, neurocognitive, and emotional/behavioral development. This pre-planned, 4-year follow-up study of the 1440 PEPaNIC patients and of 369 matched healthy children was blinded for treatment allocation (ClinicalTrials.gov-NCT01536275). Methods: Studied clinical outcomes included anthropometrics, health status, parent/caregiver-reported executive functions, and emotional/behavioral problems, and clinical tests for intelligence, visual-motor integration, alertness, motor coordination and memory. Univariable and multivariable linear and logistic regression analyses adjusted for risk factors assessed the impact of late-PN versus early-PN on the outcomes and investigated a potential mediation role of the adversely altered DNA-methylation of 37 CpG sites previously shown to be evoked by late-PN as compared with early-PN (3). Results: Overall, at 4 years follow-up, patients (356 late-PN patients, 328 early-PN patients) could be tested neurocognitively. They revealed worse anthropometric, health status, neurocognitive and emotional/behavioral developmental outcomes than the healthy control children. Outcomes of late-PN patients were never worse than those of early-PN patients. In contrast, late-PN patients had fewer internalizing (P=0.042) and externalizing problems (P=0.046), and fewer total emotional/behavioral problems (P=0.007) than early-PN patients, which were normalized by late-PN. Avoiding the early-PN induced adversely altered DNA-methylation status of the 37 CpG sites statistically explained its impact on the behavioral outcomes. Conclusion: Four years after randomization to late-PN or early-PN in the PICU, late-PN did not show harm, and was found to protect against emotional/behavioral problems, with altered DNA-methylation as a potential biological mediator hereof. These data further support de-implementation of PN-use early during critical illness in infants and children. (1) Fivez et al. N Eng J Med 2016 (2) Verstraete et al. Lancet Respir Med 2019 (3) Guiza et al. Lancet Respir Med 2020 (in press) Oxford University Press 2020-05-08 /pmc/articles/PMC7209307/ http://dx.doi.org/10.1210/jendso/bvaa046.2116 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Pediatric Endocrinology
Jacobs, An
Dulfer, Karolijn
Eveleens, Renate
Hordijk, José
Cleemput, Hanna Van
Verlinden, Ines
Wouters, Pieter
Mebis, Liese
Guerra, Gonzalo Garcia
Joosten, Koen
Verbruggen, Sascha
Güiza, Fabian
Vanhorebeek, Ilse
den Berghe, Greet Van
MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title_full MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title_fullStr MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title_full_unstemmed MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title_short MON-LB012 Long-Term Developmental Impact of Withholding Parenteral Nutrition in Pediatric-ICU: A 4-Year Follow-Up of the Pepanic Randomized Controlled Trial
title_sort mon-lb012 long-term developmental impact of withholding parenteral nutrition in pediatric-icu: a 4-year follow-up of the pepanic randomized controlled trial
topic Pediatric Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209307/
http://dx.doi.org/10.1210/jendso/bvaa046.2116
work_keys_str_mv AT jacobsan monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT dulferkarolijn monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT eveleensrenate monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT hordijkjose monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT cleemputhannavan monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT verlindenines monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT wouterspieter monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT mebisliese monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT guerragonzalogarcia monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT joostenkoen monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT verbruggensascha monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT guizafabian monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT vanhorebeekilse monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial
AT denberghegreetvan monlb012longtermdevelopmentalimpactofwithholdingparenteralnutritioninpediatricicua4yearfollowupofthepepanicrandomizedcontrolledtrial